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Papillon±LefeÁvre syndrome is an autosomal recessive
disorder characterized by palmoplantar keratoderma,
periodontitis, and premature loss of dentition.
Mutations in the CTSC gene that encodes cathepsin
C have been described in families affected with
Papillon±LefeÁvre syndrome. Cathepsin C is the least
understood of the lysosomal cysteine proteases; it has
been reported to participate in both intracellular and
extracellular cleavage of proteins and activation of
serine proteases in immune and in¯ammatory cells.
We report here eight new mutations in Papillon±
LefeÁvre syndrome families: four deletions and four
point mutations, including a missense mutation in
the propeptide chain that could help elucidate struc-
ture±function relationships in this protein. We also
found that the 458C > T mutation, ®rst reported in
two families by Hart et al (2000c), was a neutral poly-
morphism in our families, as suggested by Allende
et al (Cathepsin C gene: ®rst compound hetero-
zygous patient with Papillon±LefeÁvre syndrome and
novel symptomless mutation. Hum Mutat 17:152±153,
2001). Key words: cathepsin C mutations/chromosome
11q14/palmoplantar keratoderma/Papillon±LefeÁvre syn-
drome/periodontitis. J Invest Dermatol 117:1657±1661,
2001
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nherited palmar and plantar keratodermas (PPK) are a
heterogeneous group of skin diseases characterized by
hyperkeratosis on the palms and soles and potentially
ectodermal or nonectodermal features, such as hair and nail
anomalies, hearing loss, and mental retardation (Kelsell and
Stevens, 1999). Defects in various structural proteins such as
keratins, connexins, and desmosomal proteins have been identi®ed
as the cause of diverse variants of PPK, most of which exhibit
autosomal dominant transmission. Keratins, the major intermediate
®laments of keratinocytes, and loricrin, the major precursor protein
of the corni®ed cell envelope, are mutated in a number of diverse
epidermal disorders (Kelsell and Stevens, 1999). The desmosomal
cell±cell junctions consist of membrane proteins such as desmoglein
1 and desmoplakin, which are mutated in nonsyndromic striate
PPK (Rickman et al, 1999) and syndromic PPK with cardiomyo-
pathy and woolly hair (Norgett et al, 2000). Mutations in other
molecules involved in ®lament anchorage such as plakoglobin or
plakophilin have been shown to underlie Naxos disease (McKoy et
al, 2000) and ectodermal dysplasia/skin fragility syndrome
(McGrath et al, 1997), respectively. Furthermore, defects of gap-
junction proteins (connexins 26, 30, and 31) have been found to be
involved in a spectrum of epidermal diseases (Kelsell and Stevens,
1999). Recently, mutations in a secreted protein SLURP-1, which
is a member of the Ly-6/uPAR superfamily, were identi®ed in Mal
de Meleda (Fischer et al, 2001).
Papillon±LefeÁvre syndrome (PLS, MIM 245000) is a rare
autosomal recessive genodermatosis with an estimated incidence
of 1±4 per million (Gorlin et al, 1964). It was ®rst described by two
French dermatologists (Papillon and LefeÁvre, 1924) who mistook it
for Mal de Meleda (MIM 248300). Both diseases are diffuse PPK
with disseminated keratotic lesions, in particular on the elbows and
knees. PLS, however, is typically associated with premature loss of
deciduous and permanent teeth and a severe periodontitis. Gingival
in¯ammation, pocket formation, and bleeding of the gums develop
shortly after tooth eruption, but disappear after exfoliation
(Haneke, 1979).
The PLS gene was localized to chromosome 11q14 by
homozygosity mapping (Fischer et al, 1997; Laas et al, 1997). In
1999, two different groups (Hart et al, 1999; Toomes et al, 1999)
reported PLS to be due to mutations in the gene encoding
cathepsin C, a lysosomal cysteine protease of the papain type also
known as dipeptidyl aminopeptidase (CTSC and DPP1, MIM
602365). Shortly thereafter, Hart's group suggested that mutations
in this gene could also lead to Haim±Munk syndrome (HMS, MIM
245010), which is characterized by typical PLS symptoms as well as
hand deformities such as arachnodactyly, acroosteolysis, and
onychogryposis, in descendants of a religious isolate from
Cochin, India (Hart et al, 2000a). This group further reported
that a CTSC mutation was associated with prepubertal periodon-
titis in a consanguineous family from Jordan with no other PLS-
type symptoms (Hart et al, 2000b). Hart has subsequently noted that
additional symptoms could be due to homozygosity at other loci in
these consanguineous families, and might not be related to the
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cathepsin C mutations (Hart et al, 2000c). We have analyzed nine
families from Algeria, France, Martinique, Morocco, and the
Netherlands with PLS, and found eight novel mutations including
four deletions predicted to cause frameshifts leading to premature
termination codons. We also found that a mutation (458C > T)
leading to T153I previously described in two families (Hart et al,
2000c) was probably a neutral polymorphism, as suggested by
Allende et al (2001).
MATERIALS AND METHODS
Subject We collected whole blood samples after obtaining written
informed consent from 18 patients and 29 unaffected members of nine
families including six consanguineous kindreds. Five of these nine
families have been previously reported (Fischer et al, 1997). The families
were from Algeria (two), France (four), Martinique (one), Morocco
(one), and the Netherlands (one). All affected family members presented
symptoms typical of PLS with no evidence of hand deformities or other
symptoms reported in HMS.
Mutation analysis We ®rst designed oligonucleotide primers ¯anking
exons 1 and 2 using the Primer3 program for an optimal annealing
temperature of 58°C from the sequence U79415, which was described as
the speci®c genomic sequence of CTSC (Rao et al, 1997). We de®ned
the forward primer 5¢-CAGGGGTAACATGCAAAG-3¢ and the reverse
primer 5¢-CCCTTTACAACTGATGCAG-3¢ for the ampli®cation of
exon ``2'' (which corresponds now to exon 7), according to the reported
sequence of CTSC with two exons (Rao et al, 1997). We found
mutations in two families in this exon, but attempts to amplify exon ``1''
were repeatedly unsuccessful. As demonstrated by Toomes et al (1999),
exon 1 is actually divided into six exons. We used the published primers
of Toomes et al (1999) for ampli®cation of exons 2±6.
Based on the speci®c genomic sequence (AC011088) and by compar-
ing the complete cDNA sequence (U79415) with the HTGS (High
Throughput Genomic Sequences) database using the BLAST program,
we de®ned primers for the ampli®cation of exon 1 (forward primer 5¢-
GTCGGCTTCCTGGTAATTCT-3¢ and reverse primer 5¢-CGAATC-
CAGTCAAGATGCTC-3¢). The polymerase chain reaction (PCR) was
performed in a 50 ml volume containing 100 ng of genomic DNA (in
10 ml) using standard procedures (Vignal et al, 1993). After an initial
denaturation step at 96°C for 5 min, Taq polymerase was added at 94°C
(hot start) and 35 cycles of ampli®cation were performed consisting of
30 s at 94°C, 40 s at the optimal annealing temperature (between 55°C
and 61°C), and a 10 min terminal elongation step.
One to two microliters of puri®ed PCR products (corresponding to
20±40 ng of template) were added to 1 ml of sense or antisense primer
(10 mM) and 3 ml of BigDye terminator mix (PE Applied Biosystems).
The linear ampli®cation consisted of an initial denaturation step at 96°C,
25 cycles of 10 s of denaturation at 96°C, a 5 s annealing step (55°C±
Figure 1. Sequence variations and pedigrees
in consanguineous families F6 and F2. The
haplotypes for family F6 are also included; this
family presents a recombination event in the
monozygotic twins between the CTSC gene and
marker D11S4175 (arrow). The haplotype of the
deceased father in this family (in italics and enclosed
by brackets) has been inferred from the children's
haplotypes. Family F6 carries a seven-nucleotide
deletion beginning at nucleotide 984, and family
F2 carries a point mutation at nucleotide 628
leading to a stop codon. In addition to the
disease-causing homozygous mutation R210X in
F2, this family carries an E401K polymorphism.
Disease-causing mutations are indicated in red and
polymorphisms are in green. Filled symbols
indicate affected individuals, and open symbols
designate clinically unaffected subjects. The
disease-associated haplotype in family F6 is in
bold. wt, wildtype.
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61°C), and a 4 min extension step at 60°C. The reaction products were
puri®ed and sequenced on an Applied Biosystems Sequencer 3700. Both
strands from all patients, all family members, and controls were
sequenced for the entire coding region and the intron±exon boundaries.
RESULTS
Genotyping results in all nine families showed linkage to chromo-
some 11q14, con®rming the genetic homogeneity of this disorder.
The maximum combined lod score was 6.53 at D11S931 at Q = 0.
Haplotype analysis showed no evidence for a common haplotype in
these families, which have different geographic and ethnic origins.
In family F6, which was from a small French island, a consanguinity
of the seventh degree was reported. The haplotype in the affected
individual includes a homozygous deletion (984del7) in the CTSC
gene (Fig 1) and shows loss of homozygosity for markers
centromeric to CTSC. Interestingly, the same homozygous
haplotype for CTCS telomeric markers was also found in his
nonaffected monozygotic twin siblings. Haplotype analysis of the
twins showed that a recombination event in the maternal
chromosome had occurred between CTSC and D11S4175,
which re®ned the gene-containing interval to a 1 cM region
between D11S1780 and D11S4175. The new order of markers is
based on the physical map of the Golden Path database (http://
genome.ucsc.edu) and differs from that originally reported (Fischer
et al, 1997). Linkage analysis in this family for markers telomeric to
CTSC produced negative lod scores. Sequencing of the PCR-
ampli®ed exons 1±7 revealed 11 different mutations in our families:
four point mutations (H127P, R272P, R339C, W429C), three
nonsense mutations (C24X, Y32X, R210X), and four deletions
(711del14, 984del7, 1056delT, 1141delC) (Table I). Cathepsin C
mutations were found in all the families, and were homozygous in
the six consanguineous families, whereas the nonconsanguineous
families all presented heterozygous mutations in this gene.
Sequence variations in two of these families are presented in
Fig 1, and pedigrees and genotypes of the other affected families
are shown in Fig 2. A total of 39 control alleles were screened for
mutations in the cathepsin C gene. The previously reported
R210X and the R272P mutations (Toomes et al, 1999) were
present in an Algerian family and in two families from, respectively,
France and the Netherlands. Another previously reported variant,
R339C (Hart et al, 1999; Toomes et al, 1999), was found in one
family from Martinique. One of the new missense mutations,
W429C, occurs in the same codon as that in which both Toomes et
al (1999) and Hart et al (1999) reported a mutation leading to a stop
codon, W429X.
We also found three different polymorphisms in three families
(F2, F8, and F9) in exons 3 and 7, and in intron 4 (Fig 1,
Table II). In a consanguineous Algerian family F2 with homo-
zygous R210X mutations in affected individuals, a 1202G > A
polymorphism, which changes glutamic acid to lysine (E401K), was
present in unaffected individuals (one of the parents and two
nonaffected children). A 458C > T polymorphism, which changes
threonine to isoleucine (T153I), was present in one parent in each
of two French families (F8, F9), but not in all the affected
individuals. Ninety-®ve control individuals were screened for this
sequence variation (458C > T) in exon 3; half of them (47) were
population-matched controls from North Africa (Algeria and
Tunisia) and the other half (48) were from France. There were
66 individuals homozygous for the C allele, two individuals
homozygous for the T allele, and 27 subjects heterozygous for
C/T. The allele frequencies are therefore 0.837 for the C and 0.163
for the T. In family F8, both probands inherited a previously
reported 815C > G mutation, R272P (Toomes et al, 1999; Hart et
al, 2000c), from his father and a 1141delC mutation in exon 7 as
well as the 458C > T polymorphism probably from his mother,
who was not available for analysis. In family F9, the proband was
heterozygous for a deletion inherited from his father (1056delT
leading to a frameshift and a premature stop codon at amino acid
352) and a point mutation (W429C) inherited from his mother. As
the mother was heterozygous for the 458C > T polymorphism
(T153I, Fig 2), not transmitted to her affected son, and as she was
not affected herself, one can conclude that the 458C > T change
was not disease-causing in this family.
DISCUSSION
Identi®cation of eight new mutations in families from Europe,
Martinique, and North Africa brings the total number of reported
mutations to 36. Thirty-three of these mutations lead to PLS
exclusively, one has been suggested to cause either PLS or
prepubertal periodontitis (Y347C in exon 6), and two different
mutations in codon 286, also in exon 6, could lead either to HMS
(Q286R) or PLS (Q286X) (Toomes et al, 1999; Hart et al, 1999,
2000a, c; Allende et al, 2001; Nakano et al, 2001; Zhang et al,
2001). The 458C > T polymorphism we found in two French
families is the same as the mutation reported by Hart et al (2000c) as
disease-causing and by Allende et al (2001) as symptomless. We
demonstrated the presence of this polymorphism in population-
matched controls from France and North Africa in which we found
a frequency of 16.3% for the T allele.
Cathepsin C is a lysosomal cysteine protease of the papain type
(Paris et al, 1995). It is the least understood of the cysteine proteases
and differs from most other members of this family (cathepsin B, H,
L, and S) in both structure and substrate preference. The protein is
processed into a mature proteolytically active enzyme consisting of
a heavy chain, a light chain, and a propeptide that remains
associated with the active enzyme (Wolters et al, 1998; Cigic et al,
2000). Whereas the other cathepsins are monomers, CTSC is a
200,000 kDa tetramer with four identical subunits, each composed
of the three different polypeptide chains. All but three of the
missense mutations were found in the heavy chain of the protein,
Table I. Mutations in cathepsin C in PLS families from Europe and North Africaa
Family Origin Consanguinity Site Mutation Effect
1 Morocco + Exon 1 72C > A C24X
2 Algeria + Exon 4 628C > T R210X
3 Algeria + Exon 5 711del14 Frameshift, premature stop codon at aa 249
4 Holland + Exon 6 815G > C R272P
5 Martinique + Exon 7 1015C > T R339C
6 France + Exon 7 984del7bp Frameshift, premature stop codon at aa 330
Ile d'Yeu
7 France ± Exon 1 96T > G Y32X
± Exon 3 380A > C H127P
8 France ± Exon 6 815G > C R272P
± Exon 7 1141delC Frameshift, premature stop codon at aa 394
9 France ± Exon 7 1056delT Frameshift, premature stop codon at 352
± Exon 7 1287G > C W429C
aNovel mutations are in boldface.
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which is the most conserved region of the protein across species and
is suspected to be important for enzyme activity and speci®city
(Wolters et al, 1998). Two missense mutations (Q252L and
W429C) are in amino acids that are thought to be critical in the
active site of cysteine proteases in the heavy and light chains,
respectively. Two other mutations, H127P and W39S, are in the
propeptide chain, con®rming the importance of this peptide in
maintaining the structural stability of the mature enzyme (Cigic et
al, 2000). The enzyme can act as both an exopeptidase and an
endopeptidase (Wolters et al, 1998). It has dipeptidyl aminopepti-
dase activity with broad speci®city and a transferase activity at
alkaline and neutral pH and is activated by chloride ion, which
seems to bind to the active site (Cigic and Pain, 1999; Wolters et al,
2000). Cathepsin C is implicated in the intracellular and
extracellular cleavage of proteins, and the activation of serine
proteases such as leukocyte elastase, cathepsin G, and granzymes A
and B in immune and in¯ammatory cells. Cathepsin C can also
activate neuraminidase, factor XIII (a transglutaminase), and it
cleaves endoproteolytically some proteins of the extracellular
matrix including collagen types I, III, and IV, and ®bronectin
(Wolters et al, 1998, 2000).
The physiologic role of cathepsin C is still unclear. Expressed at
high levels in lung, kidney, and placenta (Rao et al, 1997), it is also
present in many other organs including the epithelial regions
affected by PLS, the oral keratinized gingiva (Hart et al, 1999), and
cells involved in immune and in¯ammatory reactions such as
neutrophils, alveolar macrophages, mast cells, and cytotoxic
lymphocytes. De®ciency of cathepsin C in mutant mice had no
obvious phenotypic effects, but their cytotoxic lymphocytes could
not induce granzyme A and B mediated apoptosis in target cells due
to a defect in the processing of these granzymes (Pham et al, 1997).
Electronic database GenBank accession numbers: Complete
cds, U79415; CTSC mRNA NM_001814; AC011088, BAC
clone RP11±292E14, complete genomic sequence.
BLAST (http://www.ncbi.nlm.nih.gov/BLAST)
Primer3 (http://www.genome.wi.mit.edu/cgi-bin/primer/
primer3.cgi)
Figure 2. Pedigrees and genotypes in families
F1, F3, F4, F5, F7, F8, and F9. Symbols are
the same as in Fig 1. Double horizontal lines
between parents indicate consanguineous
marriages. NA: not available.
Table II. Polymorphisms in the cathepsin C gene in
families from France and Algeria
Family Origin Site Polymorphism Effect
2 Algeria Exon 7 1202G > A E401K
8 France Exon 3 458C > T T153I
9 France Exon 3 458C > T T153I
8 France Intron 4 IVS5 + 38C > T
9 France Intron 4 IVS5 + 38C > T
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